{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Alveolar+Soft+Part+Sarcoma",
    "query": {
      "condition": "Refractory Alveolar Soft Part Sarcoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:07:30.775Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01614795",
      "title": "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Alveolar Soft Part Sarcoma",
        "Childhood Angiosarcoma",
        "Childhood Epithelioid Sarcoma",
        "Childhood Fibrosarcoma",
        "Childhood Gliosarcoma",
        "Childhood Leiomyosarcoma",
        "Childhood Liposarcoma",
        "Childhood Malignant Peripheral Nerve Sheath Tumor",
        "Childhood Synovial Sarcoma",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Osteosarcoma",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 46,
      "start_date": "2012-06-18",
      "completion_date": "2014-04-01",
      "has_results": true,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-05-22T03:07:30.775Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01614795"
    },
    {
      "nct_id": "NCT05333458",
      "title": "Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Alveolar Soft Part Sarcoma",
        "Advanced Soft Tissue Sarcoma",
        "Metastatic Alveolar Soft Part Sarcoma",
        "Refractory Alveolar Soft Part Sarcoma",
        "Unresectable Alveolar Soft Part Sarcoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2022-08-29",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T03:07:30.775Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Hartford, Connecticut • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05333458"
    },
    {
      "nct_id": "NCT06625190",
      "title": "Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Rhabdomyosarcoma",
        "Synovial Sarcoma",
        "Peripheral Nerve Sheath Tumors",
        "Clear Cell Sarcoma",
        "Alveolar Soft Part Sarcoma",
        "Desmoplastic Small Round Cell Tumor",
        "Chordoma",
        "Rhabdoid Tumor",
        "Epithelioid Sarcoma",
        "Myoepithelial Tumor",
        "Osteosarcoma",
        "Ewing Sarcoma"
      ],
      "interventions": [
        {
          "name": "Miltenyi CliniMACS Prodigy ® system",
          "type": "DEVICE"
        },
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "6 Months to 25 Years"
      },
      "enrollment_count": 27,
      "start_date": "2026-02-11",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-05-22T03:07:30.775Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06625190"
    },
    {
      "nct_id": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adrenal Cortical Carcinoma",
        "Alveolar Soft Part Sarcoma",
        "Central Nervous System Neoplasm",
        "Childhood Clear Cell Sarcoma of Soft Tissue",
        "Clear Cell Sarcoma of Soft Tissue",
        "Ewing Sarcoma",
        "Hepatoblastoma",
        "Hepatocellular Carcinoma",
        "Osteosarcoma",
        "Recurrent Adrenal Cortical Carcinoma",
        "Recurrent Alveolar Soft Part Sarcoma",
        "Recurrent Clear Cell Sarcoma of Soft Tissue",
        "Recurrent Ewing Sarcoma",
        "Recurrent Hepatoblastoma",
        "Recurrent Hepatocellular Carcinoma",
        "Recurrent Kidney Wilms Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Osteosarcoma",
        "Recurrent Primary Malignant Central Nervous System Neoplasm",
        "Recurrent Renal Cell Carcinoma",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Recurrent Thyroid Gland Medullary Carcinoma",
        "Refractory Adrenal Cortical Carcinoma",
        "Refractory Alveolar Soft Part Sarcoma",
        "Refractory Clear Cell Sarcoma of Soft Tissue",
        "Refractory Ewing Sarcoma",
        "Refractory Hepatoblastoma",
        "Refractory Hepatocellular Carcinoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Osteosarcoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Refractory Primary Malignant Central Nervous System Neoplasm",
        "Refractory Renal Cell Carcinoma",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Refractory Thyroid Gland Medullary Carcinoma",
        "Refractory Wilms Tumor",
        "Renal Cell Carcinoma",
        "Rhabdomyosarcoma",
        "Soft Tissue Sarcoma",
        "Solid Neoplasm",
        "Thyroid Gland Medullary Carcinoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "2 Years to 30 Years"
      },
      "enrollment_count": 109,
      "start_date": "2017-05-18",
      "completion_date": "2026-06-27",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T03:07:30.775Z",
      "location_count": 142,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02867592"
    },
    {
      "nct_id": "NCT01532687",
      "title": "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Alveolar Soft Part Sarcoma",
        "Adult Angiosarcoma",
        "Adult Desmoplastic Small Round Cell Tumor",
        "Adult Epithelioid Hemangioendothelioma",
        "Adult Epithelioid Sarcoma",
        "Adult Extraskeletal Myxoid Chondrosarcoma",
        "Adult Extraskeletal Osteosarcoma",
        "Adult Fibrosarcoma",
        "Adult Leiomyosarcoma",
        "Adult Liposarcoma",
        "Adult Malignant Peripheral Nerve Sheath Tumor",
        "Adult Rhabdomyosarcoma",
        "Adult Synovial Sarcoma",
        "Adult Undifferentiated Pleomorphic Sarcoma",
        "Malignant Adult Hemangiopericytoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma AJCC v7",
        "Stage IV Adult Soft Tissue Sarcoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2012-03-13",
      "completion_date": "2019-10-31",
      "has_results": true,
      "last_update_posted_date": "2021-09-27",
      "last_synced_at": "2026-05-22T03:07:30.775Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01532687"
    }
  ]
}